# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.17 by 170...
The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proc...
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.23 by 230...
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.27 by 262...
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.27 by 262...
A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone a...